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de Namur, Namur, Belgium, 2 Laboratory of Neurophysiology, Université Libre de Bruxelles, Brussels, Belgium, 3 Laboratoire
de Parasitologie, Faculté de Médecine, Université Libre de Bruxelles, Bruxelles, Belgium
Live attenuated vaccines play a key role in the control of many human and animal
pathogens. Their rational development is usually helped by identification of the reservoir
of infection, the lymphoid subpopulations associated with protective immunity as well as
the virulence genes involved in pathogen persistence. Here, we compared the course of
Brucella melitensis infection in C57BL/6 mice infected via intraperitoneal (i.p.), intranasal
(i.n.) and intradermal (i.d.) route and demonstrated that the route of infection strongly
impacts all of these parameters. Following i.p. and i.n. infection, most infected cells
observed in the spleen or lung were F4/80+ myeloid cells. In striking contrast, infected
Ly6G+ neutrophils and CD140a+ fibroblasts were also observed in the skin after i.d.
infection. The virB operon encoding for the type IV secretion system is considered
essential to deflecting vacuolar trafficking in phagocytic cells and allows Brucella to
multiply and persist. Unexpectedly, the 1virB Brucella strain, which does not persist in
the lung after i.n. infection, persists longer in skin tissues than the wild strain after i.d.
infection. While the CD4+ T cell-mediated Th1 response is indispensable to controlling
the Brucella challenge in the i.p. model, it is dispensable for the control of Brucella in
the i.d. and i.n. models. Similarly, B cells are indispensable in the i.p. and i.d. models
but dispensable in the i.n. model. γδ+ T cells appear able to compensate for the
absence of αβ+ T cells in the i.d. model but not in the other models. Taken together,
our results demonstrate the crucial importance of the route of infection for the host
pathogen relationship.
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INTRODUCTION
Live attenuated vaccines (LAVs), composed of live pathogens that are made much less virulent than
the pathogenic parental strains, are one of the most cost effective health tools in medical history
[for review see (1–3)]. The advantages of LAVs include their mimicry of natural infections, the
stimulation of long-term humoral and cellular immunity and their intrinsic adjuvant properties.
First generation LAVs relied on empirical and somewhat unpredictable attenuation. In the present
regulatory environment, the use of LAVs has been limited by safety concerns, especially due to
the risk of reversion to wild-type virulence and the possibility of causing disease in immune
compromised individuals. However, advances in immunology, molecular virology and bacteriology
have paved the way for the rational design of LAVs while avoiding the unpredictability of empirical
attenuation to thus reduce the safety risks.
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Rational design of LAVs requires good knowledge of the in
vivo infection process. In particular, the pathogen’s cell cycle,
main reservoirs of infection and the virulence genes involved
in persistence of the pathogen can be characterized in order to
help select the most effective candidate vaccines. However, one of
the biggest remaining challenges is the identification of immune
markers of protection, such as the type of T helper response
and the lymphoid subpopulations associated with protective
immunity (4). In the current study, we use the Brucella infection
in mice as a model to investigate the impact of the route of
infection on the identification of these parameters.
Brucella (an alphaproteobacterium) is a facultative
intracellular Gram-negative coccobacillus that infects wild and
domestic mammals and causes brucellosis. Human brucellosis
is among the most common zoonoses (5). The vast majority
of cases worldwide are attributed to B. melitensis [reviewed in
Pappas et al. (6)]. Although it is rarely fatal, Brucella can cause a
devastating multi-organ disease in humans with serious health
complications in the absence of prolonged antibiotic treatment
(6, 7). Human brucellosis primarily occurs following mucosal
exposure to contaminated aerosols or ingestion of contaminated
foods (8–12). However, in some occupational groups, such as
cattle dealers, butchers, veterinarians, and farmers, it is well-
documented that brucellosis can be acquired directly through
contact of broken skin with infected animals (13, 14). The
frequency of direct cutaneous infection is difficult to determine
and could be underestimated as cutaneous manifestations
of brucellosis are known to disappear spontaneously in
patients (15).
During infection, B. melitensis mainly leads a stealthy
intracellular lifestyle (16). Effector proteins secreted by the type
IV secretion system (T4SS), which is encoded by the virB operon,
are involved in the establishment of intracellular replicative
niches. B. melitensis strains lacking a functional T4SS appear
to be highly attenuated in mice and in their natural host, the
goat [reviewed in De Jong and Tsolis (17)]. In vitro experiments
using macrophage cell lines have shown that the T4SS is required
for maturation of the Brucella phagosome into an endoplasmic
reticulum-derived compartment (18).
Although the most frequent natural routes of Brucella
infection are mucosal or cutaneous, the main experimental
model for studying brucellosis in mice is intraperinoneal (i.p.)
infection, which bypasses mucosal immune defenses and leads
to infection that very rapidly becomes systemic. Over the last
decade, our group characterized the phenotype of infected
cells and the protective response against Brucella in an i.p.
model (19, 20) and compared it to a model of intranasal
(i.n.) infection (21). Taken together, those studies demonstrated
that the lymphocyte populations required to control a Brucella
challenge in each infectious model differed widely. The CD4+T
cell-mediated Th1 response and B cells are indispensable in
the i.p. model (20) but appear to be dispensable in the i.n.
model (21).
To our knowledge, there is no described experimental model
of cutaneous Brucella infection in mice. Only one study (22)
describes cutaneous injection with Brucella abortus in the
footpad of guinea pigs and the development of protective
memory. Thus, in the present study, we developed and
characterized an original intradermal (i.d.) infection model in
mice. We compared the dissemination of wild-type and virB-
deficient strains of Brucella and the type of cells infected
and the protective immune response in the i.d., i.n., and i.p.
models. This approach led us to conclude that the route of
infection has unexpected major consequences on the host-
pathogen relationship and should definitely be considered when
selecting LAVs.
MATERIALS AND METHODS
Ethics Statement
The procedures used in this study and the handling of
the mice complied with current European legislation
(Directive 86/609/EEC) and the corresponding Belgian
law “Arrêté royal relatif à la protection des animaux
d’expérience” of 6 April 2010 and published on 14 May
2010. The Animal Welfare Committee of the Université
de Namur (UNamur, Belgium) reviewed and approved the
complete protocol for Brucella melitensis infection (Permit
Number: UN-LE-13/195).
Mice and Bacterial Strains
Wild-type C57BL/6 and BALB/c mice were acquired fromHarlan
(Bicester, UK). TCR-δ−/−, CD3ε−/−, TCR-β−/−, MuMT−/−,
CCR2−/−, and CCR7−/− C57BL/6 were all purchased from The
Jackson Laboratory (Bar Harbor, ME). IFN-γR−/− (23) and IL-
12
−/−
p35 C57BL/6 mice (24) were acquired from Dr. B. Ryffel
(University of Orleans, France). IL17RA−/− C57BL/6 mice (25)
were acquired from Dr. K. Huygen (Belgian Scientific Institute
for Public Health, Brussels, Belgium). TNFR1−/− C57BL/6 (26)
were acquired from Dr. C. De Trez (Vrije Universiteit Brussel).
TAP1−/− C57BL/6 mice (27) andMHCII−/− C57BL/6 mice (28)
were acquired from Jörg Reimann (University of Ulm, Ulm,
Germany). All wild-type and deficient mice used in this study
were bred in the animal facility of the Gosselies campus of the
Université Libre de Bruxelles (ULB, Belgium). We used wild-
type strains of Brucella melitensis 16M. We also used Brucella
melitensis 16M stably expressing a rapidly maturing variant of
the red fluorescent protein DsRed (29), the mCherry protein,
under the control of the strong Brucella spp. promoter, psojA.
The construction of the mCherry-expressing Brucella melitensis
(mCherry-B) strain has been described previously in detail (30).
The 1virB mutant was constructed in the mCherry-B strain by
triparental mating to introduce the pJQ200 UC1-virB plasmid
from the E. coli DH10B strain [described in Nijskens et al. (31)]
into the mCherry-B strain using the E. coli MT 607 (pro-82 thi-
I hsd R17 (r-m+) supE44 recA56 pRK600) strain [described in
Casadaban and Cohen (32)], and the allelic replacement was
performed as described previously for other gene deletions (33).
Deletion of the virB operon was checked by PCR using the virB-
F-check 5′-CGCTCGGCTATTATGACGGC-3′ and virB-R-check
5′-CGCCGATCATAACGACAACGG-3′ primers.
Cultures were grown overnight with shaking at 37◦C in 2YT
liquid medium (Luria-Bertani broth with double quantity of
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yeast extract) and were washed twice in RPMI 1640 (Gibco
Laboratories; 3,500x g, 10min) before inoculation of the mice.
Brucella melitensis was always handled under BSL-3
containment according to Council Directive 98/81/EC of
26 October 1998 and a law of the Walloon government of 4
July 2002.
Brucella melitensis Staining With eFluor670
For some experiments, we stained Brucella melitensis with
eFluor670 labeling. Cultures were grown overnight as indicated
above and we then incubated the bacteria for 20min in
the dark with eFluor670 dye at the final concentration of
10µM. After incubation, the bacteria were washed three
times in PBS and once in RPMI before inoculation of
the mice.
Measurement of Brucella melitensis
Multiplication in vitro
The growth of Brucella melitensis in liquid culture was monitored
continuously using the multiwell Bioscreen system (Thermo
Fisher, ref. 110001-536). The B. melitensis cultures in 2YT
medium were centrifuged, washed once with PBS and diluted
to an OD600 of 0.05 in 2YT to start culture in the Bioscreen
system. Each sample (200 µl per well) was cultured at
37◦C for 48 h.
Brucella melitensis Infection in vivo
We used wild-type or mCherry-expressing Brucella melitensis
in RPMI [described in Copin et al. (30)]. Control animals were
inoculated with the same volume of PBS. The infectious
doses were validated by plating serial dilutions of the
inoculums. For i.n. infection, mice were anesthetized with
a cocktail of Xylasine (9 mg/kg) and Ketamine (36 mg/kg)
in PBS before being inoculated with 30 µl of the indicated
dose of Brucella melitensis. For i.d. infection, mice were
anesthetized by inhalation of Isofluran before injecting
20 µl of the indicated dose of Brucella melitensis. For i.p.
infection, mice were injected with 500 µl intraperitoneally
without anesthesia.
Protocol for Secondary Infection With
Brucella melitensis
C57BL/6 mice were immunized intranasally (i.n.), intradermally
(i.d.) or intraperitoneally (i.p.) as indicated, with 2× 104 CFU of
live wild type B. melitensis. The infectious doses were validated by
plating serial dilutions of inoculums. 28 days after immunization,
the mice were given antibiotics for 15 days to clear the infection.
This oral treatment was a combination of rifampicin (12 mg/kg)
and streptomycin (450 mg/kg; adapted from Vitry et al. (20)]
prepared fresh daily and given in the drinking water. To ensure
that the antibiotic treatment was effective, some mice in each
group were sacrificed 1 week prior to the challenge and the
CFU counts were evaluated in the spleen. After resting for an
additional 15 days, the mice were challenged i.n., i.d. or i.p., as
indicated with 2 × 104 CFU of live mCherry-B. melitensis and
sacrificed at the indicated times.
Footpad Lesion Monitoring
The thickness of Brucella melitensis infected footpads was
measured regularly with a metric caliper, and corresponded to
the size of the footpad lesions.
Brucella melitensis Counting in Mice
At the selected time post infection, we collected 75 µl of
blood from the mice. They were then sacrificed by cervical
dislocation. Immediately after sacrifice, the spleen, liver (one
lobe), footpad, lung (left), mediastinal lymph node, thymus,
muscle (1 square cm of thigh muscle), heart, brain, tail
(2mm), ovary, popliteal lymph node (depending on the
experiment) were collected for bacterial counting. Tissues were
crushed and transferred to PBS/0.1% X-100 Triton (Sigma-
Aldrich). We performed successive serial dilutions in PBS to
obtain the most accurate bacterial count and plated them
on 2YT agar plates. The CFU were counted after 5 days of
culture at 37◦C.
Cytofluorometric Analysis
The lungs were harvested and cut into small pieces. As
described previously (21), spleens and footpad lesions were
harvested, cut into small pieces and incubated for 1 h at 37◦C
with a mix of 100µg/ml of DNAse I fraction IX (Sigma-
Aldrich) and 1.6 mg/ml of collagenase (400 Mandl U/ml).
The cells were then washed and filtered, and incubated with
saturating doses of purified 2.4G2 (anti-mouse Fc receptor,
ATCC) in 200 µl PBS, 0.2% BSA, 0.02% NaN3 (FACS buffer)
for 20min at 4◦C to prevent antibody (Ab) binding to the
Fc receptor.
3–5 × 106 cells were stained on ice with various fluorescent
mAb combinations in FACS buffer. We acquired the following
mAbs from BD Biosciences: BV421-coupled T45-2342 (anti-
F4/80), BV421-coupled M1/70 (anti-CD11b), fluorescein
(FITC)-coupled 145-2C11 (anti-CD3ε), FITC-coupled
30-F11 (anti-CD45), FITC-coupled M1/70 (anti-CD11b),
phycoerythrin (PE)-coupled HL3 (anti-CD11c), PE-coupled
1A8 (anti-Ly6G), allophycocyanin (APC)-coupled BM8
(anti-F4/80), biotin-coupled 2G9 (anti-MHCII, I-A/I-E).
Biotin-coupled APA5 (anti-CD140a/ PDGFRA) was purchased
from eBioscience. The biotin-coupled Abs were incubated
with streptavidin-coupled APC for 30min. The cells were
analyzed on a BD FacsVerse flow cytometer. Dead cells and
debris were eliminated from the analysis according to size
and scatter.
Fluorescence Microscopy of Brucella
melitensis in vitro
Brucella melitensis strains were observed with a Nikon 80i
(objective phase contrast × 100, plan Apo) connected to
a Hamamatsu ORCA-ER camera. For the observation of B.
melitensis, 2 µl of an exponential phase culture was dropped on
an agarose pad (solution of 1% agarose in PBS) and sealed with
VALAP (1/3 vaseline, 1/3 lanoline and 1/3 paraffin wax). Images
were taken manually every 20min at 32 ◦C with NIS-Element
software (Nikon).
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Immunofluorescence Microscopy of Tissue
Spleens and lymph nodes were fixed for 2 h at RT in 2%
paraformaldehyde (PFA) (pH 7.4), washed in PBS, and incubated
overnight at 4◦C in a 20% PBS-sucrose solution. Lungs were
fixed for 20min at RT in 2% PFA. Then, lungs were placed
under a vacuum until no air was present in the lungs in 2%
PFA for 2 h. After fixation, lungs were incubated overnight
at 4◦C in a 20% PBS-sucrose solution. Tissues were then
embedded in Tissue-Tek OCT compound (Sakura), frozen in
liquid nitrogen, and cryostat sections (5µm) were prepared. For
staining, tissue sections were rehydrated in PBS and incubated in
a PBS solution containing 1% blocking reagent (Boeringer) (PBS-
BR 1%) for 20min before incubation overnight in PBS-BR 1%
containing any of the following mAbs or reagents: DAPI nucleic
acid stain Alexa Fluor 350, 488 phalloidin (Molecular Probes),
APC-coupled BM8 (anti-F4/80, Abcam), Alexa Fluor 647-
coupled M5/114.15.2 (anti-I-A/I-E, MHCII, BioLegend), Alexa
Fluor 647-coupled HL3 (anti-CD11c, BD Biosciences), biotin-
coupled 1A8 (anti-Ly6G, BioLegend), biotin-coupled APA5
(anti-CD140a/ PDGFRA, eBioscience). The biotin-coupled Ab
was incubated with streptavidin-coupled APC for 2 h. Slides were
mounted in Fluoro-Gel medium (Electron Microscopy Sciences,
Hatfield, PA). Labeled tissue sections were visualized with an
Axiovert M200 inverted microscope (Zeiss, Iena, Germany)
equipped with a high-resolutionmonochrome camera (AxioCam
HR, Zeiss). Images (1,384 × 1,036 pixels, 0.16 µm/pixel)
FIGURE 1 | Each route of infection leads to a specific pattern of infected organs. Wild-type C57BL/6 mice were intraperitoneally (i.p.), intranasally (i.n.), or
intradermally (i.d.) infected with a dose of 2 × 104 CFU of mCherry-B. melitensis and sacrificed at the indicated times. (A,B) The data represent the CFU count per ml
of blood or per spleen, as indicated. Gray bars represent the median. The significant differences between the indicated groups are marked with asterisks: *p < 0.1,
**p < 0.01, ***p < 0.001. (C) The individual kinetic CFU data are summarized in a matrix giving the median level of CFU (n = 7) by tissue according to the route of
infection. These results are representative of two independent experiments. h, hours; d, days; LN, lymph node; p.i., post infection; n, number of mice per group. (D)
Hypothetical model summarizing the spread of Brucella from the primary site of infection to the spleen for each route of infection.
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FIGURE 2 | The type of cells infected is dependent on the route of infection. Wild-type C57BL/6 mice (n = 5) were infected intraperitoneally (i.p.) (A), intranasally (i.n.)
(B), or intradermally (i.d.) (C) with a dose of 108 (A,B) or 107 (C) CFU of eFluor670 labeled B. melitensis and sacrificed at 2 and 24 h post infection. The spleen (A),
lung (B), or footpad lesion (C) were harvested and the cells were isolated and then analyzed by flow cytometry for the expression of eFluor670, CD45, F4/80,
CD140a, and CD11b as indicated. Numbers in blue indicate the percentage of eFluor670+ cells in each quadrant out of the total cells. These results are
representative of three independent experiments.
were acquired sequentially for each fluorochrome with A-
Plan 10x/0.25N.A. and LD-Plan-NeoFluar 63x/0.75N.A. dry
objectives and recorded as eight-bit gray-level ∗.zvi files. At least
3 slides were analyzed per organ from 3 different animals and the
results are representative of 2 independent experiments.
Confocal Microscopy
Confocal analyses were performed using a LSM780 confocal
system fitted on an Observer Z 1 inverted microscope equipped
with an alpha Plan Apochromat 63x/1.46 NA oil immersion
objective (Zeiss, Iena, Germany). DAPI was excited using a
405 nm blue diode, and emission was detected using a band-
pass filter (410–480 nm). The 488 nm excitation wavelength
of the Argon/2 laser was used in combination with a band-
pass emission filter (BP500-535 nm) to detect Alexa Fluor 488
phalloidin. The 543 nm excitation wavelength of the HeNe1 laser
and a band-pass emission filter (BP580–640 nm) were used for
the red fluorochromemCherry. The 633 excitation wavelength of
the HeNe2 laser and a band-pass emission filter (BP660–695 nm)
were used for far-red fluorochromes such as APC. To ensure
optimal separation of the fluorochromes, blue & red signals
were acquired simultaneously in one track and green & far red
signals were acquired in a second track. The electronic zoom
factor and stack depth were adjusted to the region of interest
while keeping image scaling constant (x-y: 0.066 micron, z: 0.287
micron). A line average of 4 was used and datasets were stored
as 8-bit proprietary ∗.czi files. The images were displayed using
Zen2012 software (Zeiss) with linear manual contrast adjustment
and exported as 8-bit uncompressed ∗.TIF images. The figures,
representing single optical sections across the region of interest,
were prepared using the Canvas program.
Enzyme-Linked Immunosorbent
Assay (ELISA)
The presence of Brucella melitensis specific murine IgM, IgG1,
IgG2a, and IgG3 was determined by ELISA. As already described
(17), polystyrene plates (269620; Nunc) were coated with HK
B. melitensis (107 CFU/mL) and incubated overnight at 4◦C. The
plates were blocked for 2 h at RT with 200 µl/well of PBS-3.65%
casein. Then, plates were incubated with 50 µl/well of plasma in
serial dilutions in PBS-3.65% casein. The plasma of uninfected
mice and PBS were used as negative controls and a 12B12 mAb
specific to Brucella LPS (34) was used as a positive control. After
four washes with PBS, isotype-specific goat anti-mouse HRP
conjugated Ab were added (50 µl/well) at appropriated dilutions
(anti-IgM from Sigma-Aldrich; LO-MG1-13 HRPO, LO-MG2a-
9 HRPO, and LO-MG3-13 HRPO from LOIMEX). After 1 h of
incubation at RT, plates were washed four times in PBS and 100
µl/well of substrate solution (BD OptEiA Kit) was added. After
15min of incubation at RT in the dark, the enzyme reaction was
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FIGURE 3 | Following intradermal infection with Brucella melitensis, fibroblasts, neutrophils, and macrophages were found to be infected in the footpad lesion.
Wild-type C57BL/6 mice were infected intradermally with a dose of 107 CFU of mCherry-B. melitensis. Mice were sacrificed at 24 h post infection and the footpad
lesions were collected and analyzed by confocal microscopy for the expression of mCherry and CD140a, LY6G, and F4/80 markers. The panels are color-coded with
the text for DAPI, the antigen examined or mCherry-Brucella. Scale bar = 5µm. Yellow arrowheads indicate the cells infected. The data are representative of two
independent experiments.
stopped by adding 25 µl/well of 2N H2SO4. The absorbance was
measured at 450 nm.
Statistical Analysis
We used a (Wilcoxon-)Mann-Whitney test provided by the
GraphPad Prism software to statistically analyse our results. Each
group of deficient mice was compared to the wild-type mice. We
also compared each group with the other groups and displayed
the results when required. Values of p < 0.05 were considered to
represent a significant difference. ∗, ∗∗, ∗∗∗ denote p < 0.05, p <
0.01, p< 0.001, respectively.
RESULTS
Each Route of Brucella Infection Is
Associated With a Specific Pattern of
Organ Infection
In order to determine the impact of the route of Brucella infection
on the pattern of infected organs in mice, we administered 2 ×
104 CFU of mCherry-Brucella melitensis via i.p., i.n. or i.d. route
to wild-type C57BL/6 mice. Mice were bled for CFU counting in
the blood and then sacrificed at 1 h, 1, 5, 12, 28, and 50 days post
infection and a large number of organs and tissues were collected
(lung and draining mediastinal lymph node (LN), spleen, liver,
thymus, skeletal muscle of the thigh, heart, brain, fragment of
the tail, ovary, footpad lesion, and draining popliteal LN) and the
CFU count was measured by plating, as described in the Material
and Methods.
Our results, presented in Figures 1A,B and Figures S1, S2,
showed drastic differences between the pattern of tissues infected
via the i.p., i.n., and i.d. routes. A table providing an overview of
the individual kinetic CFU data with the average CFU by tissue
according to the route of infection is presented in Figure 1C.
As previously reported by us, CFU are not detectable in blood
following i.n. infection (21, 35) but are detectable following i.p.
and i.d. infection (Figure 1A). However, CFU in blood were 10–
100-fold lower following i.d. infection compared to i.p. infection.
Despite these differences, which led to very different kinetics
and levels of spleen infection in the first 12 days of infection,
the spleen appears to be infected at almost comparable levels at
28 days post infection in all three models (Figure 1B). Several
interesting observations can be made based on Figure 1C which
summarizes our CFU data. They confirm that i.p. infection can be
considered as a systemic model of infection as all tissues collected
were found to be infected early and the majority of lymph nodes
tested were still infected at 50 days post infection (Figure S3).
In striking contrast, the i.n infection model produced a very
narrow infection pattern: only the mediastinal LN (draining the
lung) and spleen were infected persistently. The lung, liver, heart,
and brain were infected significantly but only transiently. The
i.d. infection model gave an intermediate infection pattern. The
skin footpad lesion, popliteal LN (draining the footpad lesion),
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FIGURE 4 | The essentiality of virB is dependent on the route of infection and organ. Wild-type C57BL/6 mice were infected intraperitoneally (i.p.) (A), intranasally (i.n.)
(B) or intradermally (i.d.) (C), with a dose of 2 × 104 CFU of mCherry-B. melitensis or with mCherry-1virB B. melitensis. Mice were sacrificed at the indicated times.
The data represent the CFU count per lung, spleen, or footpad lesion. Gray bars represent the median. Significant differences between the indicated groups are
marked with asterisks: *p < 0.1, **p < 0.01, ***p < 0.001. These results are representative of two independent experiments. h, hours; d, days; n, number.
mediastinal LN, spleen, and liver were infected persistently.
Skeletal muscle and the brain were only infected transiently.
Importantly, we observed that Brucella persists over the long
term, until 50 days post infection, mainly in lymphoid tissues,
such as the LN and spleen, in all models and in the thymus in
the i.p. model. A proposed model for the spread of Brucella from
the primary site of infection to the spleen in the three models of
infection is presented in Figure 1D.
The Type of Cells Infected Depends on the
Route of Infection
In the past (30, 36), we have used a Brucella melitensis 16M
strain expressing the mCherry fluorescent tracer to detect
and phenotype Brucella infected cells in situ by fluorescent
microscopic analysis. However, this approach is very long and
is not appropriate for the quantitative analysis of many organs.
Flow cytometry analysis would be more suitable. Unfortunately,
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FIGURE 5 | The 1virB B. melitensis strain multiplies differently depending on
the tissue. Wild-type C57BL/6 mice were infected intraperitoneally (i.p.) (A),
intranasally (i.n.) (B) or intradermally (i.d.) (C), with a dose of 107 CFU of
eFluor670 labeled mCherry-B. melitensis or with eFluor670 labeled
mCherry-1virB B. melitensis. Mice were sacrificed at the indicated times and
the spleen, lung or footpad was harvested, fixed and analyzed by fluorescent
microscopy. The data represent the percentage of eFluor670 negative bacteria
among mCherry positive bacteria. Bars represent the standard deviation.
Significant differences between the indicated groups are marked with
asterisks: **p < 0.01, ***p < 0.001. These results are representative of two
independent experiments with 3 mice per condition. h, hours; n, number of
bacteria analyzed in each condition.
in the absence of an available yellow laser, the fluorescence of the
mCherry-Brucella strain is too low to permit the direct detection
of infected cells by flow cytometry. To avoid this technical
problem, we developed a protocol using the dye eFluorTM 670
(eFluor670) that produces intense fluorescent staining of the
bacterial cell wall. Brief incubation of bacteria with eFluor670
leads to intense, stable and homogeneous staining of Brucella that
FIGURE 6 | 1virB B. melitensis actively multiplies in the footpad lesion.
Wild-type C57BL/6 mice were infected intradermally (i.d.) with a dose of 107
CFU of eFluor670 labeled wild-type or 1virB mCherry-B. melitensis. Mice were
sacrificed at 24 h post infection and the footpad was harvested, fixed, and
analyzed by confocal microscopy. (A,B) show representative images for
wild-type or 1virB mCherry-B. melitensis, respectively. The panels are
color-coded with the text for DAPI, Phalloidin, mCherry, and eFluor670. Scale
bar = 5µm. pos, positive; neg, negative.
can be detected by flow cytometry (Figure S4A. This staining
does not negatively affect Brucella growth in vitro in a rich
medium culture (Figure S4B) or in mice in the i.n (Figure S4C)
and i.p. infection models (Figure S4D).
As shown in Figure 2, eFluor670 staining allowed for
rapid flow cytometric detection and quantification of Brucella
infected cells present within tissues harvested at 2 and 24 h
from infected mice. Our data confirm that, as previously
reported by microscopic analysis, infected spleen cells in
the i.p. model (30) (Figure 2A) and infected lung cells in
the i.n. model (37) (Figure 2B) are mainly CD45+ F4/80+
myeloid cells, presumably red pulp macrophages and alveolar
macrophages, respectively. In striking contrast, the same analysis
of footpad lesion cells from the i.d. infection model showed
that two clearly distinct cell populations, CD45neg and CD45+,
are infected by Brucella (37) (Figure 2C). Infected CD45neg
cells express high levels of the CD140a fibroblast marker
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FIGURE 7 | Intradermally infected IFNγR and TNFR1−/− mice display
significant footpad swelling and CFU counts. Wild-type, IL12p35−/−,
IFNγR−/−, IL-17RA−/−, and TNFR1−/− C57BL/6 mice were infected
intradermally with a dose of 2 × 104 CFU of mCherry-B. melitensis. (A) At the
indicated time post infection, the swelling of the lesion was measured for each
mouse. The error bars are the SD. (B) At the indicated times, mice were
sacrificed and the footpad, draining popliteal lymph node, and spleen were
harvested. The data represent the CFU count per organ. Gray bars represent
the median. The significant differences between the indicated groups are
marked with asterisks: **p < 0.01, ***p < 0.001. These data are representative
of two different experiments. d, days; n, number; LN, lymph node.
and infected CD45+ cells express CD11b myeloid markers
(Figure S5), which can be subdivided into CD11b+ F4/80+
Ly6Gneg/med and CD11b+ F4/80neg/med Ly6Ghigh (Figure S6).
Confocal microscopic analysis of footpad samples collected
at 24 hours from infected mice demonstrated that CD140+,
Ly6G+, and F4/80+ cells are indeed infected and display
typical morphology of fibroblasts, neutrophils, and macrophages,
respectively (Figure 3).
On the whole, these data showed that the type of cells infected
by Brucella is strongly dependent on the route of infection.
Although the infected cells are mainly macrophages in the i.p.
and i.n. models, fibroblasts, and neutrophils are also infected in
the i.d. model.
Identification of Virulence Factors Is
Affected by the Route of Infection and
Organ Analyzed
In the rational development of LAVs, it is essential to identify
virulence factors allowing for escape from the immune response
and persistence in the host. LAVs must be able to establish
infection in order to stimulate an adaptive immune response
without persisting or disseminating deeply in the host. The most
studied virulence factor in Brucella is undoubtedly the virB T4SS.
In vitro in RAW 264.7 macrophages, a 1virB Brucella strain is
unable to escape the phagolysosome system and appears to be
highly attenuated (38).
In order to determine the impact of the route of infection on
the type of virulence factors required to establish a successful
infection in vivo, we compared the course of wild-type and
1virB Brucella strains in wild-type C57BL/6 mice (Figure 4).
As previously described (39), the 1virB Brucella strain appears
attenuated but able to persist for several weeks in the spleen in
the i.p infection model (Figure 4A). In this model, we observed
that the 1virB Brucella strain is also attenuated in the lung. It
persists at∼100 CFU between 2 h and 5 days post infection and is
no longer detectable from 28 days. In striking contrast, in the i.n.
model (Figure 4B), the1virB Brucella strain appears completely
unable to multiply in the lung and reach the spleen. In the lung,
the number of CFU drops by 3 log between 2 h and 5 days post
infection. A complemented 1virB strain recovers the ability to
multiply in the lung, demonstrating that the inability of the1virB
strain to persist in the lung is specific and related to the virB
deficiency only (Figure S7). More surprising, in the i.d. model,
the 1virB strain persists longer in the primary footpad lesion
than the wild-type Brucella strain. At 50 days post infection, the
1virB strain is still present in the footpad while the wild-type
strain has already disappeared at 28 days (Figure 4C). In the
spleen, the1virB strain remains attenuated (Figure 4C).
The differing behavior of the1virB strain observed depending
on the route of infection and the tissue may be due to a
difference in the ability to actively multiply or to passively
persist (i.e., persistence without multiplication). Brucella has
been widely described to display atypical unipolar growth (40).
Unlabelled daughter cells can be visualized upon the resumption
of growth following staining of the bacteria with Texas red
conjugated to succinimidyl ester (TRSE) (41). Here, we chose
to replace TRSE with eFluor670 staining, which is compatible
with the mCherry Brucella strain. Thus, newly formed bacteria,
called “newborn” bacteria, appear as mCherry+ eFluor670neg
(Figure S8A). We confirmed by fluorescence microscopy the
stability and absence of transfer of eFluor670 staining during
Brucella growth and division in vitro (Figure S8B). Using this
tool, we tried to quantify multiplication of the wild-type and
1virB Brucella strains in situ. Mice were infected by i.p., i.n.
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FIGURE 8 | IFNγR deficiency leads to the massive recruitment of neutrophils in dermal tissue. Wild-type, IFNγR−/−, IL-17RA−/−, and TNFR1−/− C57BL/6 mice
were infected intradermally with a dose of 2 × 104 CFU of mCherry-B. melitensis. Control wild-type mice were injected with PBS. Mice were sacrificed at 3 days post
infection and the footpad was harvested and analyzed by fluorescent microscopy. The panels are color-coded with the text for DAPI, phalloidin, mCherry-B.melitensis,
and LY-6G. Scale bar = 100µm. These data are representative of two different experiments.
or i.d. route with eFluor670-stained wild-type mCherry-B and
1virB mCherry-expressing Brucella strains. 24 and 48 h later,
mice were sacrificed and the organs of interest were harvested
and analyzed by confocal microscopy. Figures 5A–C show
the frequencies of mCherry+ eFluor670neg (newborn) bacteria
among the mCherry+ bacteria in the spleen, lung and footpad
lesion at 24 and 48 h post infection from i.p., i.n., or i.d. infected
mice, respectively. Figure 6 presents representative images from
infected footpads. As expected, wild-type Brucella appears able to
multiply in all tissues analyzed based on the abundant presence of
mCherry+ eFluor670neg newborn bacteria at 48 h post infection.
The frequency of newborn Brucella in the spleen from wild-type
and 1virB Brucella infected mice was similar (Figure 5A). In
contrast, the frequency of newborn Brucella in the lung from
1virB Brucella infected mice is strongly reduced (∼15 times)
compared to wild-type Brucella infected mice (Figure 5B). In
the footpad lesion, the situation appears to be intermediate. The
frequency of newborn Brucella from1virB Brucella infectedmice
is only reduced by∼2-fold. These results suggest that the absence
of persistence of 1virB Brucella in the lung is due to a reduced
ability to multiply and that persistence in the spleen and footpad
lesion is associated with active multiplication.
We can conclude that the impact of virB deficiency appears
vary widely as a function of the route of infection and organ
analyzed, suggesting that the identification of virulence factors
could be strongly impacted by these parameters.
In the next part of this article, we will focus on the impact
of the route of infection on the type of immune response
and lymphocyte populations involved in primary and secondary
control of Brucella melitensis infection.
Th1 Immune Response Is Crucial to
Control of the Primary Cutaneous
Brucella Infection
To our knowledge, the type of immune mechanism underlying
cutaneous Brucella infection has never been investigated in a
mouse model. As reported in i.p. (42) and i.n. (21) infectious
models, BALB/c mice appear to be more susceptible to cutaneous
B. melitensis infection compared to C57BL/6 mice (Figure S9).
In order to identify the T helper subset of immune response
associated with Brucella control in skin lesions, we compared
the course of Brucella melitensis infection in wild-type, IL-
12
−/−
p35 , IFNγR
−/−, IL-17RA−/−, and TNFR1−/− C57BL/6 mice.
We observed that Brucella infection in wild-type and IL-
17RA−/− mice leads to moderate footpad lesions at 3 days post
infection that disappeared spontaneously at 7 days (Figure 7A).
The lesions persisted longer in IL-12
−/−
p35 mice, but regressed
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FIGURE 9 | Impact of CCR2 and CCR7 deficiency on the course of
intradermal Brucella infection. Wild-type, CCR2−/−, and CCR7−/− C57BL/6
mice were infected intradermally with a dose of 2 × 104 CFU of B. melitensis
and sacrificed at the indicated times. The data represent the CFU count per
organ. Gray bars represent the median. The significant differences between
the indicated groups are marked with asterisks: *p < 0.1, **p < 0.01, ***p <
0.001. These results are representative of three independent experiments. LN,
lymph node; d, days; n, number.
spontaneously at 14 days. In striking contrast, lesions in
IFNγR−/− and TNFR1−/− mice displayed uncontrolled growth
until 14 days (Figure 7A) and become necrotic (data not
shown). Growth and necrosis of the lesion were higher in
IFNγR−/− mice. The severity of the footpad lesion in all
groups of mice appeared to be closely correlated with the
corresponding CFU level (Figure 7B). We have previously
reported (21) a dramatic difference between IL-12
−/−
p35 and
IFNγR−/− mice in control of a Brucella infection in the i.n.
infection model. In this model, IFNγR−/− mice, but not IL-
12
−/−
p35 mice, display severe neutrophilia and succumb to the
infection, suggesting that this lack of control and mortality result
from the complete absence of IFN-γ and are not proportional to
its level.
Fluorescent microscopic analysis of the footpad lesion at 3
days in wild-type, IL-17RA−/− and TNFR1−/− infected mice
showed a moderate presence of neutrophils, identified by Ly-
6G staining (Figure 8). In contrast, the dermis of the lesion
from infected IFNγR−/− mice displayed very intense neutrophil
recruitment. This was confirmed by flow cytometric analysis of
the footpad lesion (Figure S10A). In wild-type mice, Brucella
infection led to the recruitment of CD11b+ F4/80+ Ly6Gneg
monocytes that peaked at 7 days post infection with only
moderate recruitment of CD11b+ F4/80neg Ly6G+ neutrophils.
In infected IFNγR−/− mice, neutrophils constituted the major
population in the footpad lesion and the frequency of monocytes
appeared to be strongly reduced (Figure S10B).
As our microscopic analysis showed that F4/80+
monocytes/macrophages appear to be infected by Brucella
in the skin of i.d. infected mice (Figure 3) and their recruitment
is correlated with the control of Brucella (Figure S10B), we
investigated the impact of chemokine receptor CCR2 and CCR7
deficiency on Brucella control in our i.d. infection model.
Monocyte emigration from bone marrow during bacterial
infection requires signals mediated by CCR2 (43) but seems to
be dispensable for the maintenance of dermal macrophages and
dendritic cells (44). In contrast, CCR7 regulates the migration
of inflammatory monocytes (45), and dendritic cells (46) from
skin to the draining lymph node under inflammatory conditions.
We observed that i.d. infected CCR2−/− mice display delayed
monocyte recruitment and a higher rate of neutrophils at 7 days
post infection in the footpad lesion (Figure S10B) associated
with an increased CFU count in the footpad lesion, popliteal
draining LNs, and spleen (Figure 9), confirming the importance
of monocyte recruitment in the local and systemic control of
Brucella infection. Interestingly, CCR7 deficiency led to retention
of Brucella in the lesions and seemed to delay its dissemination
to the popliteal draining LNs and spleen, suggesting that Brucella
dissemination is partially dependent on monocyte and dendritic
cell migration. In agreement, flow cytometry analysis of footpad
lesions and popliteal draining LNs from mice i.d. infected with
eFluor670+ bacteria showed that, while the eFluor670+ cells
in the lesion are mainly CD11c and MHCII negative, they
are mostly positive in the LNs (Figures 10A–C). Interestingly,
the frequency of CD11c+ MHCII+ infected dendritic cells is
drastically reduced in CCR7−/− mice compared to wild-type
mice (Figure 10C).
Finally, using a battery of genetically-deficient C57BL/6 mice,
we investigated the role of lymphoid populations in the control
of i.d. Brucella melitensis infection. Comparison of the course of
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FIGURE 10 | CCR7 deficiency reduced the frequency of infected dendritic cells in popliteal draining lymph nodes. Wild-type and CCR7−/− C57BL/6 mice were
infected intradermally with a dose of 107 CFU of eFluor670+ labeled B. melitensis and sacrificed at 24 h post infection. The footpad lesion and the popliteal draining
lymph nodes were harvested and the cells were isolated and then analyzed by flow cytometry for the expression of eFluor670, MHCII, and CD11c as indicated. The
data represent the frequency of eFluor670+ cells in cells from footpad lesions (A) and popliteal draining lymph nodes (B) and the phenotype of eFluor670+ cells in
these tissues (C). Percentage indicates the percentage of cells in each quadrant out of the total cells (A,B) or of the eFluor670+ cells (C). LN, lymph node. These
results are representative of three independent experiments.
Brucella infection in wild-type, CD3−/− (deficient for T cells),
TCR-δ−/− (deficient for γδT cells), TCR-β−/− (deficient for both
CD4+T and CD8+T cells), MHCII−/− (deficient for CD4+T
cells), TAP1−/− (deficient for CD8+Tcells), and MuMT−/−
(deficient for B cells) mice showed that CD4+T cells are strictly
required for Brucella control in the footpad lesion and popliteal
draining lymph node (Figure 11). Interestingly, CD4+T cells
appear to be dispensable in the spleen, as only CD3 and TCR-β
deficiency negatively impaired Brucella control there. CD8+T cell
deficiency significantly favored Brucella control in the draining
lymph node but not in the lesion or spleen. This may be the
consequence of the higher number of CD4+T cells in absence
of CD8+T cell in TAP1−/− mice. In a previous study (47), we
demonstrated that even though the amounts of IFN-γ produced
by CD8+T cells and CD4+T cells are similar, CD8+T cells
are unable to replace CD4+T cells in their control of Brucella
infection, suggesting that CD4+T cells deploy as yet unidentified
effector mechanisms that may be independent of IFN-γ. In
the i.d. infection model, γδ+T cells appeared to be dispensable
for the control of i.d. Brucella infection. Despite the detectable
humoral response (Figure S11A), similar to that observed in the
i.p. infection model (Figure S11B), B cells also appeared to be
dispensable. However, though the finding was not statistically
significant, we did observe a repeated tendency of MuMT mice
to display increased CFU counts in draining lymph nodes at 50
days post infection (Figure 11).
Taken together, our data demonstrate that the control of
primary cutaneous Brucella infection mainly required an IFN-γ-
mediated Th1 response, TNF-α production and CD4+ T cells but
not an IL-17RA-mediated Th17 response. They also show that
monocyte recruitment plays a crucial role in both the control and
dissemination of cutaneous Brucella infection.
The Type of Immune Response Controlling
Secondary Brucella Infection Is Dependent
on the Route of Infection
In order to establish the main features of the protective immune
response induced by i.d. Brucella infection, we started by
comparing the course of i.d. mCherry-B. melitensis infection in
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FIGURE 11 | Impact of various lymphocytes deficiencies on the course of intradermal Brucella infection. Wild-type, CD3−/−, TCRαβ−/−, TCRγδ−/−, MHCII−/−,
TAP1−/−, and MuMT−/− C57BL/6 mice were infected intradermally with a dose of 2 × 104 CFU of B. melitensis and sacrificed at the indicated times. The data
represent the CFU count per organ. Gray bars represent the median. The significant differences between the indicated groups are marked with asterisks: *p < 0.1,
**p < 0.01, ***p < 0.001. These results are representative of three independent experiments. LN, lymph node; d, days; n, number.
naive mice (primary infection group) and in mice previously i.d.
infected with wild-type-B. melitensis for 28 days and then treated
with antibiotics (secondary infection group), as described in the
Material and Methods.
Antibiotic treatment is indispensable to the comparison of
wild type and genetically deficient mice. It is well known that the
persistence of a pathogen generates chronic inflammation and
can cause a “Mackaness effect”(48, 49). Without antibiotics, the
level of persistence of the vaccine strain would be very different
between wild-type mice and mice deficient for key components
of the immune response against Brucella, which would make our
results very difficult to interpret. It has been reported that Rev1
infection in sheep (50, 51) and rams (52) is fully cleared between
the second and third month after subcutaneous or conjunctival
vaccination. Thus, by eliminating the primary infection at 28
days in our experimental model, we are not so far away from the
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FIGURE 12 | Comparison of protection in control mice and mice previously immunized with live B. melitensis. C57BL/6 mice were immunized intradermally (i.d.) with
2 × 104 CFU of live wild type B. melitensis and treated with antibiotics, as described in the Materials and Methods. Naive (primary infection group) and immunized
(secondary infection group) mice were challenged i.d. with 2 × 104 CFU of live mCherry-B. melitensis and sacrificed at the indicated times. The data represent the
CFU count per organ or per ml of blood. Gray bars represent the median. Significant differences between the indicated groups are marked with asterisks: *p < 0.1,
**p < 0.01, ***p < 0.001. These results are representative of three independent experiments. LN, lymph node; d, days; h, hours; n, number.
conditions of the natural host vaccinated with the reference Rev1
vaccine against Brucella melitensis.
Our results (Figure 12) demonstrated that i.d. infection leads
to the development of an adaptive immune response able to
efficiently control secondary i.d. infection in the footpad lesion,
blood, popliteal draining lymph node and spleen. It is interesting
to note that while Brucella is almost completely eliminated in
the footpad lesion, blood, and spleen, it nevertheless persists at
a significant level in the lymph nodes, suggesting that it may be
sheltered from the adaptive immune response at this site.
The type of immune mechanism required for the protective
secondary immune response appears to be dramatically
dependent on the tissue analyzed. As shown in genetically-
deficient mice, effective control in the footpad lesion is
dependent on TNFR1 and IL-17RA but not IL-12p35 and,
in the spleen, is dependent on TNFR1 but not IL-17RA and
IL-12p35. In the popliteal lymph node, the absence of IL-12p35,
IL-17RA, or TNFR1 does not have a significant impact on the
CFU count (Figure 13). Similarly, only CD4+T cells, and no
other lymphoid populations, are essential to control Brucella
in the footpad lesion, but CD4+T cells are dispensable in the
popliteal draining lymph node and spleen. In the spleen, B cells
are strictly required but only the absence of all T cells in CD3−/−
mice leads to a significant loss of Brucella control, suggesting
that the absence of a T cell subpopulation can be compensated
for by the other subpopulations in this organ. Unexpectedly,
the absence of T cells in CD3−/− mice, and especially of
CD8+T cells in TAP1−/− mice, improved the control of Brucella
in popliteal draining lymph nodes, suggesting that Brucella
persistence there implicates CD8+T cells (Figure 14). Regulatory
CD8+CD122+PD-1+T cells, which are located in lymph nodes
and act in a non-antigen-specific manner, have been described
in persistent viral infection (53, 54). These cells have not been
described in a Brucella model but could be responsible for
this phenomenon.
It would also have been interesting to test the ability of
IFN-γR−/− mice to develop a protective memory response
against Brucella. However, these mice develop highly necrotic
footpad lesions and, for ethical reasons, we therefore limited our
observations of these mice to 14 days post infection.
Lastly, to summarize the impact of the route of infection on
the type of protective immune memory response, we compared
the results obtained in the i.d. infection model with those
obtained by our group in the i.p. (20) and i.n. (21) infection
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FIGURE 13 | Comparison of protection in wild-type and various deficient mice
previously immunized by intradermal route with live B. melitensis. Wild-type,
IL-12p35−/−, TNFR1−/−, IL-17RA−/− C57BL/6 mice were immunized
intradermally (i.d.) with 2 × 104 CFU of live wild-type B. melitensis and treated
with antibiotics, as described in the Materials and Methods. Naive (primary
infection group) and immunized (secondary infection group) mice were
challenged i.d. with 2 × 104 CFU of live mCherry-B. melitensis and sacrificed
at 12 days post infection. The data represent the CFU count per organ. Gray
bars represent the median. The significant differences between the indicated
groups are marked with asterisks: *p < 0.1, **p < 0.01. These results are
representative of three independent experiments. LN, lymph node; n, number.
FIGURE 14 | Comparison of protection in wild-type and various
lymphocyte-deficient mice previously immunized by intradermal route with live
B. melitensis. Wild-type, CD3−/−, TCRαβ−/−, TCRγδ−/−, MHCII−/−,
TAP1−/−, and MuMT−/− C57BL/6 mice were immunized intradermally (i.d.)
with 2 × 104 CFU of live wild-type B. melitensis and treated with antibiotics, as
described in the Materials and Methods. Naive (primary infection group) and
immunized (secondary infection group) mice were challenged i.d. with 2 × 104
CFU of live mCherry-B. melitensis and sacrificed at 12 days post infection. The
data represent the CFU count per organ. Gray bars represent the median. The
significant differences between the indicated groups are marked with
asterisks: **p < 0.01, ***p < 0.001. These results are representative of three
independent experiments. LN, lymph node; n, number.
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models (Figure 15). Note that the requirements were completed
in the i.p. model to allow for a full comparison with other
models (Figure S12). Figure 15 shows clearly that the type
of lymphoid cells and T helper response required to control
secondary Brucella infection is strongly dependent on the route
of infection and the tissues infected. For example, CD4+T
cells are indispensable in the footpad lesion in the i.d. model
and in the spleen in the i.p. model but are dispensable in
the spleen level in both the i.d. and i.p. models. B cells are
indispensable in the i.d. and i.p. models but dispensable in the
i.n. model. The IL-12p35 dependent Th1 response is only required
in the spleen in the i.p. model and in the footpad lesion in
the i.d. model. It is dispensable in the i.d. and i.n. models in
the spleen. Thus, we can conclude that the identification of
immune markers associated with protection against infection
is strongly affected by the route of infection used and the
organ analyzed.
DISCUSSION
There are well-documented cases in which generalization of use
of a new drug favors, in just a few decades, the development
of resistance leading to treatment failure [reviewed in Zur
Wiesch et al. (55)]. This problem has become so acute that drug
resistance is viewed as one of the major challenges in public
health, reinforcing the importance of vaccines in the control
of epidemics.
Historically, highly successful global vaccination campaigns
have been associated with the administration of live-attenuated
vaccines (LAVs) (1). Today, modern vaccination strategies focus
mainly on the use of subunit vaccines (SUVs) with an adjuvant
(56–58). Compared to LAVs, SUVs offer several advantages:
(i) their supposed safety because they exclude all risks of
reversion of attenuated pathogens to a virulent form, (ii) their
high specificity limiting the risk of autoimmune diseases, and
(iii) the ease to produce, conserve, and transport them. But
the benefits of SUVs hide some weaknesses. In addition to
their classical antigen- or target-specific protective effects, LAVs
can induce non-specific protective effects. Epidemiological data
suggest that vaccination with smallpox, measles, BCG or oral
polio vaccines results in increased overall childhood survival
[reviewed and discussed in Benn et al. (59) and de Bree et al.
(60)]. These observations can be partially explained by the
poly-specificity of antigenic T and B receptors, the Mackaness
effect and the induction of innate immune memory (trained
immunity) (61). SUVs drive immune responses against a reduced
number of dominant antigens and are associated with a modern
adjuvant selected for its low inflammatory potential. Because
this design reduces the possibilities of TCR and BCR-mediated
cross-protection and a short-lived, low level of activation of
innate immune response, it limits the possibility of non-specific
protection. More importantly, vaccine resistance, although rare,
is now well-documented for several SUVs (62). This seems
mainly due to single mutational events, suggesting that small
variations of pathogens can allow them to escape to sharp antigen
selection pressure generated by SUVs. These weaknesses of SUVs,
combined with the growth of antibiotic resistance, could in the
near future leave us extremely helpless in the face of epidemics.
One solution to this problem is the rational development
of second-generation LAVs retaining the efficiency of first-
generation LAVS but compatible with current safety standards.
This goal is achievable thanks to our better understanding of
the genetics of microorganisms. However, we lack a rigorous
methodology for selecting candidate vaccines in animal models.
Ideally, an effective and safe LAV should induce strong
and adapted mucosal and systemic immunity against the
target pathogen, without persisting or disseminating in the
host. This requires, in particular, that the natural niche
of pathogen persistence, the virulence genes necessary for
pathogen persistence and the immune markers associated with
the protective memory state be identified. The vast majority
of studies attempting to identify these factors in animal
experimental models are carried out using a single route of
infection. Often, for historical or convenience reasons, a single
route of infection is considered as the reference. In the case
of studies to select candidate vaccines against Brucella in mice
models, the reference is the intraperitoneal (i.p.) route (63)
that leads to a rapid systemic infection. Rare studies use the
more physiological intranasal (i.n.) or oral infection routes.
The purpose of the present study was to highlight the impact
of the route of infection on the identification of infection
niches, virulence genes and immune markers associated with
the development of a protective immune memory in the
Brucellamodel.
We took advantage of the fact that we have already studied
the reservoir of infection and the type of protective immune
response in the i.p. (19, 20, 30) and i.n. (21, 36) Brucella infection
models. In order to include a third model of infection in our
comparison, we developed and characterized an original model
of intradermal (i.d.) infection in this study. Contamination by
cutaneous route is not the most common for Brucella, but it is
however well-documented in certain occupational groups (13–
15).We have chosen to characterize this route, rather than amore
common type of Brucella contamination such as the oral route,
because of its technical simplicity and because a large number
of vaccines are given subcutaneously, including some Brucella
vaccines in animals.
We observed that, following i.d. infection, Brucella
disseminates immediately into the spleen and liver through
the bloodstream and reaches the popliteal draining LNs in
24 h. Brucella is detected later in the mediastinal lymph nodes,
muscles, and brain. At 50 days post infection, Brucella persists
only in the spleen and LNs. As expected, control of the primary
cutaneous infection requires a functional IL-12p35/IFNγ axis,
TNFα, as well as CD4+T cells. CD8+ T cells, γδ+T cells, B cells
and IL-17RA deficiencies appear to be dispensable. Thus, the
i.d. model seems to be similar to the i.p. model (19). It differs
strongly from the i.n. infection model which requires γδ+T cells
and IL-17RA to control Brucella during the early phase of lung
infection (21).
The i.d. model is characterized by recruitment of monocytes
and neutrophils at sites of skin infection in association with
transitory moderate swelling. A deficiency of CCR2 results in a
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FIGURE 15 | Summary of the immune response components indispensable to the control of secondary Brucella infection as a function of the route of infection.
Wild-type, CD3−/−, TCRαβ−/−, TCRγδ−/−, MHCII−/−, TAP1−/−, MuMT−/−, IL-12p35−/−, and IL-17RA−/− C57BL/6 mice were infected intradermally (i.d.),
intranasally (i.n.) or intraperitoneally (i.p.) with 2 × 104 CFU of live wild-type B. melitensis and treated with antibiotics, as described in the Materials and Methods. Naive
(primary infection group) and immunized (second infection group) mice were challenged i.d., i.n., or i.p. with 2 × 104 CFU of live mCherry-B. melitensis and sacrificed
at 12 days post infection (for i.d.) or 28 days post infection (for i.n. and i.p.). The data represent a qualitative approximation of the CFU count per organ in the present
article (i.d. model and Figure S8 for i.p. model) or in our group’s previous article characterizing the i.p. (20) and i.n. (21) models. The CFU counts of mice which do not
control the secondary infection are in red. “/”, not tested. Note that “Th1 or Th17” indicates that the Th1 response can compensate for the absence of the Th17
response and vice versa.
delay in the recruitment of monocytes and a transitory lack of
Brucella control at the cutaneous lesion and popliteal draining
LN. IFNγR deficiency also reduces monocyte recruitment and
is associated with a strong influx of neutrophils in the footpad
lesion, development of necrosis and a high CFU count in the
lesion, LN, and spleen. In contrast, as previously reported by
us (21), in the i.n. Brucella infection model, monocyte and
neutrophil recruitment is not observed in the lung and CCR2
deficiency does not affect the control of infection. Interestingly,
in the i.d. model, CCR7 deficiency leads to a significant reduction
of the spread of Brucella from the footpad lesion to the draining
LN and the spleen at 1 and 3 days post infection, and an
important increase in the number of bacteria in the cutaneous
lesion at 7 and 14 days. Taken together, our data suggest that
recruited monocytes play a key role in the control of Brucella
in the i.d. model. They also suggest that dissemination of
Brucella from the primary lesion to the draining LN and spleen
could implicate CCR7-dependent cell migration. In agreement,
Archambaud et al. (37) have shown that Brucella can migrate
from the lung to draining LNs by infecting dendritic cells and
alveolar macrophages.
An original and surprising observation in the i.d. infection
model is the inability of the protective memory response
to prevent establishment of Brucella in popliteal draining
lymph nodes. The memory response eliminates Brucella in the
cutaneous lesion, blood, and spleen, but fails to control Brucella
in the draining LN, suggesting that there is a special reservoir
protecting Brucella in this tissue. These LN reservoir cells should
be better characterized, as von Bargen et al. (64) reported that LNs
constitute the first site of Brucella infection and multiplication
during oral infection in mice and humans. Unfortunately, in
our i.d. model, the low CFU counts in LNs at later times of
infection did not allow us to analyse the LN reservoir cells by
flow cytometry and made it very difficult to visualize them by
fluorescence microscopy.
By comparing i.p., i.n., and i.d. models, we observed that
the host-pathogen relationship is strongly affected by the route
of infection.
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First, the pattern of tissue infection appears to vary widely
depending on the route of infection. The i.p. route of infection
leads to immediate systemic dissemination of Brucella to all
tissues tested. In contrast, i.n. infection displays a more restricted
pattern of infected tissues, including mainly the lung, mediastinal
draining LNs and spleen. The i.d. model presents an intermediate
pattern, with systemic dissemination to the spleen and liver and
localized strong persistence of Brucella in the cutaneous lesion
and popliteal draining LNs. The impact of the route of infection
on the spread of bacteria has already been documented by
whole body imaging inmice with radiolabelled or bioluminescent
bacteria. However, only high bacteria levels in tissues is detected
by this approach. Consequently, high doses of bacteria need to
be administered and weakly infected organs are not identified.
In the Francisella model (65), 2 × 109 radiolabelled bacteria
were administrated and their dissemination was only monitored
until 20 h post infection. Inmodels using bioluminescent Brucella
melitensis (66) and Brucella suis (67), 1× to 2.5 × 107 bacteria
were injected. In the spleen of mice infected with 2.5 × 107
CFU of B. melitensis, no bioluminescence was detected despite
the detection of 4.8 × 103 CFU by plating (66), confirming the
very poor sensitivity of bioluminescence detection. In contrast,
though time-consuming, our classical approach based on the
plating of select tissues detects up to 10 bacteria per tissue and
allows us to use a moderate dose of infection, 2 × 104 CFU
per mouse. Our results showed that, at 50 days post infection,
Brucella persists mainly in lymphoid organs, such as the spleen
and LNs in the three models, but also in the thymus in the i.p.
model. However, our goal here was not to identify all possible
Brucella persistence sites in mice and Brucella may persist in
other tissues, such as the bone marrow as recently described (68).
Second, using eFluor670 labeled Brucella, we demonstrated
that the type of cells infected first depends on the route of
infection. As previously observed, we confirmed that the main
cells infected in the lung of i.p. and i.n. infected mice at 2
and 24 h post infection were F4/80+ red pulp macrophages (30)
and alveolar macrophages (37), respectively. Surprisingly, we
observed that, in addition to F4/80+ monocytes/macrophages,
Ly6G+ neutrophils and CD45neg CD140a+ fibroblasts also
appear to be infected in the footpad lesion of i.d. infected wild-
type mice. Brucella-infected neutrophils have been described
in pathological conditions (69). To our knowledge, this is the
first description of Brucella-infected fibroblasts in vivo in wild-
type mice. Infection by Brucella of neutrophil and fibroblasts
in the footpad lesions was confirmed by confocal microscopy.
The infection of different cell types can have a significant impact
on the persistence of Brucella. It has been observed in vitro
that the intracellular trafficking of Brucella is dependent on the
type of cells infected. For example, Brucella abortus replicates
in a vacuole derived from the LAMP1neg endoplasmic reticulum
in epithelial cells, macrophages and dendritic cells, although in
extravillous trophoblasts it replicated within single-membrane
acidic LAMP1pos inclusions (70).
Third, we observed that the route of infection affects the
identification of a major virulence gene. The 1virB Brucella
strain, known to be attenuated in the i.p. infection model but
able to persist for several weeks in the spleen (39), is unable
to persist beyond 48 h in the lung in the i.n. infection model
but, surprisingly, persists longer than the wild-type strain in
cutaneous lesions in the i.d. infection model. This unexpected
result is probably due in part to the different type of cells
infected. It has been reported that 1wadC (unable to encode
LPS core glysosyltransferases) Brucella abortusmultiplies in bone
marrow-derived macrophages, RAW264.7 macrophages or HeLa
cells but is killed in bone marrow-derived dendritic cells (71).
Microscopic analysis showed that the 1virB Brucella melitensis
strain multiplies very weakly in alveolar macrophages, ∼15-fold
less than the wild type strain. In striking contrast, it multiplies at
the same level as the wild-type strain in splenic macrophages and
at an intermediate level in dermal cells,∼2-fold less than the wild
type strain. This slightly lower multiplication rate of the 1virB
Brucella strain in the footpad lesion may make Brucella more
stealthy and thus less detectable by the immune system and able
to persist longer than the wild type strain. Taken together, our
data lead us to conclude that a bacterial strain can be considered
as attenuated or not depending on the route of infection and the
tissues analyzed.
Fourth, we demonstrate that the route of infection also affects
the identification of immunemarkers associated with a protective
memory response. As summarized in Figure 15, which compares
the results obtained in this article in the i.d. infection model as
well as those obtained previously by us in the i.p. (20) and i.n.
(21) infection models, Brucella control in the spleen in challenge
conditions required different lymphocyte subsets and T helper
responses depending on the route of infection. Control in the
i.p. model appears to be dependent on IL-12p35, CD4
+T cells
and B cells (20). In the i.n. model, only αβ+T cells appear
to be strictly required. A deficiency of CD4+T cells, CD8+T
cells, B cells or IL-12p35 has no significant impact on Brucella
control in the spleen. Only the simultaneous deficiency of IL-
12p35 and IL17RA leads to a lack of control (21). Finally, in the
i.d. infection model, B cells appear to be indispensable, like in the
i.p. model, but CD4+T cells are required in the lesion but not
in the spleen. More surprisingly, Brucella control in the lesion
required IL-17RA, whereas it was not necessary for control of the
primary infection. And conversely, IL-12p35, which is needed to
control the primary infection, is no longer essential to control the
challenge in the lesion.
It may seem surprising that, depending on the route
of infection, control of Brucella in the same organ, the
spleen, requires different types of lymphocyte populations and
different T helper responses. These different needs may be the
consequence of the specific immune conditions prevailing at
the primary infection site in the different models. It is well-
established that the composition of immune and stromal cells,
as well as the phenotype of those cells, the nature of the
microenvironment and the isotypes of the antibodies differ in
each tissue and affect the ability of the immune system to control
both infections and tumor growth [reviewed in Engwerda et al.
(72) and Pao et al. (73)]. Therefore, depending on the route
of infection and on the primary infection site, the bacterial
load reach in the blood and spleen may differ significantly.
We observed this in practice when comparing our 3 models
(Figure 1D). The need for B cells is correlated with the rapid
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spread of bacteria in the blood, like in the i.p. and i.n. models. In
the i.n. model, B cells are not needed and Brucella is not detected
in the blood at any time. The same reasoning can be applied to
the requirement for IL-12p35. IL-12p35 is indispensable in the
spleen only in the i.p. model, where the bacterial load reaching
the spleen is the highest. Regardless of the dose reaching the
organ over time, Brucella could also reach the spleen in different
forms depending on the route of infection. During the first
24 h following i.p. infection, Brucella is found in the blood in
extracellular form (35). In the i.n. model, Brucella disseminates
from the lung to draining lymph nodes inside dendritic cells and
alveolar macrophages (37). Therefore, Brucella could reach the
spleen by being protected from antibodies within a cell, which
would explain that B cells are not necessary.
The route of infection has been reported to impact the nature
of the protective immune response in certain other infection
models. For example, control of an i.p. Listeria monocytogenes
challenge strictly requires memory CD4+ and CD8+ αβ+T
cells producing IFNγ (74). But in the oral L. monocytogenes
infection model, intestinal multifunctional γδ+T cells able to
simultaneously produce IFNγ and IL-17A can provide enhanced
protection against infection and even compensate for the absence
of αβ+T cells (75). However, the impact of different routes
of infection on the type of protective memory response is
rarely compared and should be more systematic in view of
its importance.
One of the major interests of our comparison of the i.p.,
i.n., and i.d. infection routes is that all of our experiments were
conducted using the same strains of Brucella melitensis 16M and
C57BL/6 mice, with the same infectious dose and under the same
animal facility conditions. There is a large body of available data
on mice infected i.p. or i.n. by Brucella in the literature. It is
very difficult, however, to truly compare the data from these
models because the infectious doses and the strains of Brucella
and mice are often different. For example, the study of Hielpos
et al. (76) showed that B. abortus persisted at high levels in the
lungs for at least 7 days and was detected in the spleen as early
as 24 h p.i., much earlier than in our i.n. model of infection.
However, BALB/cmice, that aremore susceptible to Brucella than
the C57BL/6 strain, were used in the Hielpos study and were
infected with 106 CFU of B. abortus, at a dose 50 times higher
than our infection dose. Under these experimental conditions, it
is therefore quite normal that Brucella was detected in the spleen
much faster than in our model. Even though the experimental
conditions seem similar, it is well-known that, depending on the
animal facility conditions, the immunological experience of mice
can affect their ability to control an infection non-specifically
and that a strain of bacteria can drift in the laboratory and
present slightly different virulence. Consequently, comparisons
between different models of in vivo infections that are not
performed under exactly the same experimental conditions are
often hazardous.
It is important to point out that, since the mouse is not
the natural host of Brucella melitensis, we do not consider
that one particular route of infection in a mice model is more
physiological or informative than another regarding what is
happening in the natural host during a Brucella infection. This
work must be seen as fundamental research work carried out
with the aim of improving the methodology for the rational
design of LAVs in animal models. However, our comparison
of three routes of infection allows us to draw some practical
conclusions. We observed that both the humoral response
and the cellular response are essential to the control of a
challenge in the i.p. and i.d. models, which is not the case in
the i.n. model where a humoral response and even αβT cells
are dispensable. As discussed previously, this can be explained
by the fact that the i.p. and i.d. routes of infection lead to
massive dissemination of Brucella in the blood, which is not
the case for the i.n. route. Likewise, in sheep, inoculation by
the subcutaneous route produced wider and more generalized
infections than the conjunctival route (50). Thus, the i.p. and
i.d. routes lead to systemic infection that therefore appears to
be more difficult to control than a mucosal i.n. infection and
consequently may be a more demanding test in mice for assessing
the protective capacity of a vaccine candidate. If we compare
i.p. and i.d. models, the latter display the advantage of being
close to the subcutaneous vaccination route conventionally used
with the REV1 B. melitensis vaccine in small ruminants. The
i.d. model of infection in mice also displays a pattern of tissue
infection that is quite similar to that described in the goat
(77) following subcutaneous infection with a virulent strain of
Brucella melitensis. Thus, for these reasons, i.d. could constitute a
new promising route of delivery for tests of candidate vaccines in
a mouse model.
In summary, our study demonstrates that the identification of
candidate LAVs and immune protection markers in an animal
model can be strongly affected by the route of infection used. We
therefore recommend that researchers systematically compare
different routes of infection, identified as those closest possible
to the natural host infection, and not be limited to the analysis
of a single tissue type. As the infectious doses (78) as well as the
strain of pathogen analyzed (79) can also strongly affect the type
of protective immune response, as has been well-documented in
the experimental mouse model of Leishmania major infection,
we can conclude that the selection process of candidate LAVs is
much more complex than expected.
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Figure S1 | Each route of infection leads to a specific pattern of infected organs
(part 1). Wild-type C57BL/6 mice were infected intraperitoneally (i.p.), intranasally
(i.n.) or intradermally (i.d.) with a dose of 2 × 104 CFU of mCherry-B. melitensis
and sacrificed at the indicated times. The data represent the CFU count per
footpad lesion, popliteal LN, lung, or mediastinal LN. Gray bars represent the
median. The significant differences between the indicated groups are marked with
asterisks: ∗p < 0.1, ∗∗p < 0.01, ∗∗∗p < 0.001. These results are representative of
two independent experiments. LN, lymph node; h, hours; d, days; n, number of
mice per group.
Figure S2 | Each route of infection leads to a specific pattern of infected organs
(part 2). Wild-type C57BL/6 mice were infected intraperitoneally (i.p.), intranasally
(i.n.) or intradermally (i.d.) with a dose of 2 × 104 CFU of mCherry-B. melitensis
and sacrificed at the indicated times. The data represent the CFU count per
skeletal muscle, heart, tail, brain, liver, or ovary. Gray bars represent the median.
The significant differences between the indicated groups are marked with
asterisks: ∗p < 0.1, ∗∗p < 0.01, ∗∗∗p < 0.001. These results are representative of
two independent experiments. h, hours; d, days; n, number of mice per group.
Figure S3 | Intraperitoneal Brucella infection leads to infection of a large panel of
lymph nodes. Wild-type C57BL/6 mice were infected intraperitoneally (i.p.) with a
dose of 2 × 104 CFU of mCherry-B. melitensis and sacrificed at 50 days post
infection. The data represent the CFU count per lymphoid organs (spleen, right
inguinal LN, right axillary LN, mediastinal LN, mesenteric LN, and right popliteal
LN). Gray bars represent the median. These results are representative of two
independent experiments. LN, lymph node; n, number of mice per group.
Figure S4 | Impact of eFluor670 staining on Brucella growth in vitro and in vivo.
(A) 4 × 104 CFU/ml of mCherry-B. melitensis were prepared from an overnight
liquid culture and stained with the eFluor670 fluorochrome. Bacteria were fixed
and then analyzed by flow cytometry. (B) Comparison by Bioscreen analysis of the
growth of mCherry-B. melitensis and eFluor670 stained mCherry-B. melitensis in
rich medium (2YT). These data represent the mean of three independent
experiments. (C) Wild-type C57BL/6 mice were infected i.n. with a dose of 2 ×
104 CFU of mCherry-B. melitensis or eFluor670 labeled mCherry-B. melitensis
and sacrificed at 5 or 12 days post infection. The data represent the CFU count
per lung. (D) Wild-type C57BL/6 mice were infected i.p. with a dose of 105 CFU
of mCherry-B. melitensis eFluor670 labeled mCherry-B. melitensis and sacrificed
at 5 or 12 days post infection. The data represent the CFU count per spleen.
These results (C,D) are representative of two independent experiments. Gray bars
represent the median. d, days; n, number. The significant differences between the
indicated groups are marked with asterisks: ∗p < 0.1.
Figure S5 | Phenotype of infected footpad lesion cells from wild type mice.
Wild-type C57BL/6 mice were infected intradermally with 107 CFU of
B. melitensis. Control wild-type mice were injected with PBS. The footpad lesions
were harvested at 2 or 24 h post infection and the cells were analyzed by flow
cytometry. The data result from the flow cytometry analysis of eFluor670, CD45,
CD140a, and CD11b expression on footpad cells. The data show the
representative dot plot from individual mice. These results are representative of
three independent experiments.
Figure S6 | Phenotype of infected CD11b-positive footpad lesion cells from wild
type mice. Wild-type C57BL/6 mice were infected intradermally with 107 CFU of
B. melitensis. Control wild-type mice were injected with PBS. The footpad lesions
were harvested at 2 or 24 h post infection and the cells were analyzed by flow
cytometry. The data result from the flow cytometry analysis of eFluor670, F4/80,
Ly6G, and CD11b expression on footpad cells. The data show the representative
dot plot from individual mice. These results are representative of three
independent experiments.
Figure S7 | Complemented 1virB strain growth in the lung. Wild-type C57BL/6
mice were infected i.n. with a dose of 105 CFU of wild type mCherry-B. melitensis,
1virB mCherry- B. melitensis or complemented 1virB mCherry-B. melitensis
(1virB mCherry-B. melitensis pvirB). Mice were sacrificed at 5 days post infection
and the lung was collected. The data represent the CFU count per lung. Gray bars
represent the median. Significant differences between the indicated groups are
marked with asterisks: ∗∗p < 0.01, ∗∗∗p < 0.001. These results are representative
of two independent experiments. n, number of mice per group.
Figure S8 | eFluor670 labeling identified newborn Brucella. mCherry Brucella
melitensis is labeled with eFluor670. (A) Schematic representation of unipolar
growth of eFluor670 labeled mCherry-Brucella. As eFluor670 does not move in
the bacterial membrane, the newly formed bacterium, called the newborn, loses
the eFluor670 labeling, allowing its identification by fluorescent microscopy. (B)
Representative image at 0 and 24 h of eFluor670 labeled mCherry-Brucella
extracellular growth in vitro. The 24 h image shows a division and a newborn cell
(mCherry+ eFluor670−). The panels are color-coded with the text for mCherry and
eFluor670. Scale bar = 5µm. h, hours; n, newborn; pos, positive; neg, negative.
Figure S9 | BALB/c mice are more susceptible to cutaneous Brucella infection
than C57BL/6 mice. Wild-type C57BL/6 and BALB/c mice were infected
intradermally with a dose of 2 × 104 CFU of B. melitensis and sacrificed at the
indicated times. The data represent the CFU count per organ. Gray bars represent
the median. The significant differences between the indicated groups are marked
with asterisks: ∗p < 0.1, ∗∗p < 0.01, ∗∗∗p < 0.001. These results are
representative of two independent experiments. LN, lymph node; d, days; n,
number of mice per group.
Figure S10 | Neutrophils constitute the major population in the footpad lesion
from infected IFNγR−/− mice. Wild-type, IFNγR−/−, and CCR2−/− C57BL/6
mice were infected intradermally with a dose of 2 × 104 CFU of mCherry-B.
melitensis. Control wild-type mice were injected with PBS. The footpad lesions
were harvested at 3 and 7 days post infection and the cells were analyzed by flow
cytometry. (A) Flow cytometry analysis of CD11b, F4/80, and LY6G expression on
footpad cells. The data show the representative dot plot from individual mice. (B)
Data represent the mean frequency (n = 4) of neutrophils and monocytes in the
footpad lesion at the indicated time of infection. These results are representative of
three independent experiments. Cont, control; d, days.
Figure S11 | Humoral immune response induced by intradermal Brucella
infection. Wild-type C57BL/6 mice were infected intradermally (A) or
intraperitoneally (B) with a dose of 2 × 104 CFU of mCherry-B. melitensis. Serum
was collected at the indicated times, and ELISA was performed to determine the
isotype distribution of the Brucella-specific antibodies. The data represent the
means ± SEM of results for 8 mice. These results are representative of three
independent experiments. O.D, optical density; d, days.
Figure S12 | Comparison of protection in wild-type and various deficient mice
previously immunized by intraperitoneal route with live B. melitensis. Wild-type,
TCRγδ−/−, MHCII−/−, TAP1−/−, Il-12p35−/−, and IL-17RA−/− C57BL/6 mice
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were immunized i.p. with 2 × 104 CFU of live wild-type B. melitensis and treated
with antibiotics, as described in the Materials and Methods. Naive (primary
infection group) and immunized (secondary infection group) mice were challenged
i.p. with 2 × 104 CFU of live mCherry-B. melitensis and sacrificed at 12 days post
infection. The data represent the CFU count per spleen. Gray bars represent the
median. The significant differences between the indicated groups are marked with
asterisks: ∗∗p < 0.01. These results are representative of two independent
experiments. n, number of mice per groups.
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